212 related articles for article (PubMed ID: 32060845)
1. The Multifaceted Roles of CXCL9 Within the Tumor Microenvironment.
Neo SY; Lundqvist A
Adv Exp Med Biol; 2020; 1231():45-51. PubMed ID: 32060845
[TBL] [Abstract][Full Text] [Related]
2. Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma.
Dengel LT; Norrod AG; Gregory BL; Clancy-Thompson E; Burdick MD; Strieter RM; Slingluff CL; Mullins DW
J Immunother; 2010; 33(9):965-74. PubMed ID: 20948440
[TBL] [Abstract][Full Text] [Related]
3. Immune-mediated modulation of breast cancer growth and metastasis by the chemokine Mig (CXCL9) in a murine model.
Walser TC; Ma X; Kundu N; Dorsey R; Goloubeva O; Fulton AM
J Immunother; 2007; 30(5):490-8. PubMed ID: 17589289
[TBL] [Abstract][Full Text] [Related]
4. CXCL9: evidence and contradictions for its role in tumor progression.
Ding Q; Lu P; Xia Y; Ding S; Fan Y; Li X; Han P; Liu J; Tian D; Liu M
Cancer Med; 2016 Nov; 5(11):3246-3259. PubMed ID: 27726306
[TBL] [Abstract][Full Text] [Related]
5. Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer.
Bronger H; Kraeft S; Schwarz-Boeger U; Cerny C; Stöckel A; Avril S; Kiechle M; Schmitt M
Breast Cancer Res; 2012 Feb; 14(1):R30. PubMed ID: 22333315
[TBL] [Abstract][Full Text] [Related]
6. The Distinct Roles of CXCR3 Variants and Their Ligands in the Tumor Microenvironment.
Reynders N; Abboud D; Baragli A; Noman MZ; Rogister B; Niclou SP; Heveker N; Janji B; Hanson J; Szpakowska M; Chevigné A
Cells; 2019 Jun; 8(6):. PubMed ID: 31216755
[TBL] [Abstract][Full Text] [Related]
7. Chemokine monokine induced by IFN-gamma/CXC chemokine ligand 9 stimulates T lymphocyte proliferation and effector cytokine production.
Whiting D; Hsieh G; Yun JJ; Banerji A; Yao W; Fishbein MC; Belperio J; Strieter RM; Bonavida B; Ardehali A
J Immunol; 2004 Jun; 172(12):7417-24. PubMed ID: 15187119
[TBL] [Abstract][Full Text] [Related]
8. The CC and CXC chemokines: major regulators of tumor progression and the tumor microenvironment.
Bikfalvi A; Billottet C
Am J Physiol Cell Physiol; 2020 Mar; 318(3):C542-C554. PubMed ID: 31913695
[TBL] [Abstract][Full Text] [Related]
9. Analysis of cysteine-X-cysteine motif chemokine ligands 9, 10, and 11, their receptor CXCR3, and their possible role on the recruitment of immune cells at the maternal-conceptus interface in pigs.
Han J; Gu MJ; Yoo I; Choi Y; Jang H; Kim M; Yun CH; Ka H
Biol Reprod; 2017 Jul; 97(1):69-80. PubMed ID: 28859287
[TBL] [Abstract][Full Text] [Related]
10. Targeting CXCL9/10/11-CXCR3 axis: an important component of tumor-promoting and antitumor immunity.
Pan M; Wei X; Xiang X; Liu Y; Zhou Q; Yang W
Clin Transl Oncol; 2023 Aug; 25(8):2306-2320. PubMed ID: 37076663
[TBL] [Abstract][Full Text] [Related]
11. Expression and role of MIG/CXCR3 axis in mantle cell lymphoma.
Zhu MX; Wan WL; Hong Y; Wang YF; Dong F; Jing HM
Exp Cell Res; 2020 Dec; 397(2):112365. PubMed ID: 33197439
[TBL] [Abstract][Full Text] [Related]
12. Review: The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity--a tale of conflict and conundrum.
Müller M; Carter S; Hofer MJ; Campbell IL
Neuropathol Appl Neurobiol; 2010 Aug; 36(5):368-87. PubMed ID: 20487305
[TBL] [Abstract][Full Text] [Related]
13. The chemokine receptor CXCR3 mediates rapid and shear-resistant adhesion-induction of effector T lymphocytes by the chemokines IP10 and Mig.
Piali L; Weber C; LaRosa G; Mackay CR; Springer TA; Clark-Lewis I; Moser B
Eur J Immunol; 1998 Mar; 28(3):961-72. PubMed ID: 9541591
[TBL] [Abstract][Full Text] [Related]
14. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade.
House IG; Savas P; Lai J; Chen AXY; Oliver AJ; Teo ZL; Todd KL; Henderson MA; Giuffrida L; Petley EV; Sek K; Mardiana S; Gide TN; Quek C; Scolyer RA; Long GV; Wilmott JS; Loi S; Darcy PK; Beavis PA
Clin Cancer Res; 2020 Jan; 26(2):487-504. PubMed ID: 31636098
[TBL] [Abstract][Full Text] [Related]
15. Recruitment of natural killer cells in advanced stages of endogenously arising B-cell lymphoma: implications for therapeutic cell transfer.
Przewoznik M; Hömberg N; Naujoks M; Pötzl J; Münchmeier N; Brenner CD; Anz D; Bourquin C; Nelson PJ; Röcken M; Mocikat R
J Immunother; 2012 Apr; 35(3):217-22. PubMed ID: 22421939
[TBL] [Abstract][Full Text] [Related]
16. Hepatectomy leads to loss of TRAIL-expressing liver NK cells via downregulation of the CXCL9-CXCR3 axis in mice.
Yano T; Ohira M; Nakano R; Tanaka Y; Ohdan H
PLoS One; 2017; 12(10):e0186997. PubMed ID: 29088306
[TBL] [Abstract][Full Text] [Related]
17. Dermatomyositis and MIG.
Ragusa F
Clin Ter; 2019; 170(2):e142-e147. PubMed ID: 30993311
[TBL] [Abstract][Full Text] [Related]
18. Rheumatoid arthritis and the Th1 chemokine MIG.
Paparo SR
Clin Ter; 2019; 170(6):e472-e477. PubMed ID: 31696912
[TBL] [Abstract][Full Text] [Related]
19. [Expression and significance of chemokine CXC receptor 3, 4 and their ligands at the early pregnancy decidua and villi].
Bai XX; Kong BH; Zhang YZ; Qu X; Wang HL
Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):904-8. PubMed ID: 19134328
[TBL] [Abstract][Full Text] [Related]
20. CXCL9 chemokine in ulcerative colitis.
Elia G; Guglielmi G
Clin Ter; 2018; 169(5):e235-e241. PubMed ID: 30393811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
